Oncology Peer Review On-The-Go: Is Next-Generation Sequencing a Right for Patients with GI Cancers?

Podcast

The newest episode of “Oncology Peer Review On-The-Go” features 2 competing opinions on next-generation sequencing for the treatment of gastrointestinal cancers.

In the latest episode of “Oncology Peer Review On-The-Go,” CancerNetwork examines a Q&A piece in the August issue of the journal ONCOLOGY discussing next-generation sequencing for gastrointestinal (GI) cancers. The article is titled “Ushering in the Era of Precision Medicine” and it focuses on a conversation with Tanios Bekaii-Saab, MD, of the Mayo Clinic in Phoenix, Arizona.

For a responding perspective, CancerNetwork spoke with Howard Hochster, MD, of the Rutgers Cancer Institute of New Jersey. Dr. Hochster, who is also co-editor in chief of ONCOLOGY, discussed his feelings regarding next-generation sequencing, and suggests alternative ways to treat patients with GI cancers.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Recent Videos
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Related Content